Novartis Reports Phase 2 Data for Liraglutide in Diffuse large B-cell lymphoma

Novartis today announced Phase 2 results for liraglutide in patients with diffuse large B-cell lymphoma. The study demonstrated that liraglutide reduces disease progression risk compared to standard of care or placebo. These results provide important insights into the treatment of diffuse large B-cell lymphoma and support the continued development of liraglutide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.